Abstract Number: 1342 • ACR Convergence 2020
Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK
Background/Purpose: Etanercept (ETN) is effective and well tolerated in patients with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is limited information on the effects of withdrawing…Abstract Number: 1465 • ACR Convergence 2020
The Impact of the Combined Vaccination Scheme Against Streptococcus Pneumoniae on the Incidence of Related Infections in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARD: Data from BIOBADASER 3.0
Background/Purpose: Respiratory infections are among the leading causes of hospitalization in rheumatoid arthritis (RA) and Streptococcus Pneumoniae (SP) is one of the most frequent pathogens…Abstract Number: 1840 • ACR Convergence 2020
A Novel Biomarker Identifies Systemic Lupus Erythematous (SLE) Patients Who Benefit from Obexelimab (XmAb®5871) Treatment
Background/Purpose: We previously reported Phase 2 SLE trial results for obexelimab, a CD19-targeted FcγRIIb engager that suppresses B-cell activation [1]. The primary endpoint, which measured…Abstract Number: 0124 • ACR Convergence 2020
Appropriate Timing of Denosumab Dosing and Subsequent Therapy After Discontinuation: An Academic Medical Center Experience
Background/Purpose: Denosumab, a monoclonal antibody that binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) is a popular choice for osteoporosis therapy. However,…Abstract Number: 0236 • ACR Convergence 2020
Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial
Background/Purpose: The subcutaneous (SC) formulation of CT-P13 received marketing authorization for RA from the EMA by demonstrating non-inferiority compared to CT-P13 intravenous for efficacy in…Abstract Number: 0365 • ACR Convergence 2020
Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)
Background/Purpose: Apremilast is the one targeted immune modulating (TIM) treatment for psoriatic arthritis (PsA) that may be combined with csDMARDs, biologic therapies, or used as…Abstract Number: 0579 • ACR Convergence 2020
Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients
Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapies are commonly prescribed for rheumatoid arthritis (RA) treatment. However, their high out-of-pocket (OOP) cost may limit patient access…Abstract Number: 0805 • ACR Convergence 2020
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Background/Purpose: SB5, an adalimumab biosimilar received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I and…Abstract Number: 0880 • ACR Convergence 2020
Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks
Background/Purpose: Axial SpA (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac (SI) joints and has two subtypes that represent the spectrum of…Abstract Number: 1009 • ACR Convergence 2020
Missing Data and Multiple Imputation in Rheumatoid Arthritis Registries Using Sequential Random Forest Method
Background/Purpose: Missing data in clinical epidemiological researches violate the intention to treat principle, reduce statistical power and can induce bias if they are related to…Abstract Number: 1347 • ACR Convergence 2020
Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study
Background/Purpose: Identification of predictive clinical factors of long-term treatment response in non-radiographic axial spondyloarthritis (nr-axSpA) may contribute to improved management of patients with this chronic…Abstract Number: 1477 • ACR Convergence 2020
Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic
Background/Purpose: Adherence to treatments for chronic rheumatic diseases is influenced by many factors, including the patient's belief in the development of adverse effects such as…Abstract Number: 1845 • ACR Convergence 2020
Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol: A Matched Case-Control Study
Background/Purpose: Targeting B-cells remains an attractive option in Lupus Nephritis (LN) despite the negative results of RCTs.Methods: Sixty patients with active LN were included in…Abstract Number: 0163 • ACR Convergence 2020
Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Background/Purpose: Few studies have explored cost consequences of non-persistence in the treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors (SC-TNFi) in Inflammatory Arthritis (IA; rheumatoid arthritis…Abstract Number: 0238 • ACR Convergence 2020
Gestational Desire and Certolizumab Pegol in Patients with Chronic Inflammatory Rheumatic Disease. Preliminary Results of the GESTAMAD Cohort
Background/Purpose: INTRODUCTION The use of biological therapies during pregnancy has been contraindicated since the beginning of the use of these drugs. In recent years several…
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 54
- Next Page »